CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

Anti-CTLA-4-antibodies can induce long-lasting tumor remissions. However, only a few patients respond, necessitating the development of predictive companion biomarkers. Increasing evidence suggests a major role of epigenetics, including DNA methylation, in immunology and resistance to immune checkpo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Immunol Immunother
Main Authors: Fietz, Simon, Zarbl, Romina, Niebel, Dennis, Posch, Christian, Brossart, Peter, Gielen, Gerrit H., Strieth, Sebastian, Pietsch, Torsten, Kristiansen, Glen, Bootz, Friedrich, Landsberg, Jennifer, Dietrich, Dimo
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2020
Assuntos:
Research Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8139923/
https://ncbi.nlm.nih.gov/pubmed/33196890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02777-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares